Urogen Pharma Ltd

자세한 내용은 Urogen Pharma Ltd 회사

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

회사 정보

회사 코드URGN

회사 이름Urogen Pharma Ltd

상장일May 04, 2017

설립일2004

CEOMs. Elizabeth A. (Liz) Barrett

직원 수235

유형Ordinary Share

회계 연도 종료May 04

주소9 Ha'ta'asiya St

도시RA'ANANA

증권 거래소NASDAQ Global Market Consolidated

국가Israel

우편 번호4365007

전화97297707601

웹사이트https://www.urogen.com/

회사 코드URGN

상장일May 04, 2017

설립일2004

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

--

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.94K

--

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

32.51K

+28.89%

Mr. James A. Robinson, Jr.

Independent Director

--

Dr. Mark P. Schoenberg, M.D.

Chief Medical Officer

--

Ms. Cynthia M. Butitta

Independent Director

--

Dr. Leana S. Wen, M.D.

Independent Director

--

Mr. Christopher Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

--

Mr. Vincent Perrone

Investor Relations

--

Mr. Daniel G. Wildman

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

--

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.94K

--

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

32.51K

+28.89%

Mr. James A. Robinson, Jr.

Independent Director

--

Dr. Mark P. Schoenberg, M.D.

Chief Medical Officer

--

Ms. Cynthia M. Butitta

Independent Director

--

수익 분석

통화: USD업데이트 시간: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

사업별USD

이름

수익

비율

Jelmyto

90.40M

0.00%

데이터 없음

사업별

지역별

사업별USD

이름

수익

비율

Jelmyto

90.40M

0.00%

주주

업데이트 시간: 16 hours ago

주주 통계

유형

주주 통계

주주

비율

RTW Investments L.P.

8.32%

RA Capital Management, LP

6.95%

UBS Asset Management (Switzerland)

5.73%

Menora Mivtachim Insurance Ltd.

4.99%

Vestal Point Capital, LP

4.67%

Other

69.34%

주주 통계

주주

비율

RTW Investments L.P.

8.32%

RA Capital Management, LP

6.95%

UBS Asset Management (Switzerland)

5.73%

Menora Mivtachim Insurance Ltd.

4.99%

Vestal Point Capital, LP

4.67%

Other

69.34%

유형

주주

비율

Investment Advisor

27.55%

Investment Advisor/Hedge Fund

24.49%

Hedge Fund

23.99%

Research Firm

8.75%

Insurance Company

6.73%

Venture Capital

3.28%

Corporation

2.97%

Bank and Trust

2.55%

Individual Investor

2.05%

기관 주식 보유

업데이트 시간: Tue, Mar 4

보고 기간

기관 수

보유 주식

비율

변동

2025Q1

278

43.89M

96.97%

-2.00M

2024Q4

280

43.94M

103.24%

-1.94M

2024Q3

262

44.13M

104.63%

-2.19M

2024Q2

247

46.02M

111.40%

+11.07M

2024Q1

255

34.96M

99.86%

+5.57M

2023Q4

237

29.16M

94.80%

+4.33M

2023Q3

238

25.93M

86.41%

+2.69M

2023Q2

222

19.52M

83.40%

-392.05K

2023Q1

221

19.00M

81.20%

-1.17M

2022Q4

218

18.34M

79.80%

-1.99M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

RTW Investments L.P.

3.83M

8.32%

+47.45K

+1.25%

Dec 31, 2024

UBS Asset Management (Switzerland)

1.36M

2.94%

+1.36M

--

Dec 31, 2024

Menora Mivtachim Insurance Ltd.

2.30M

5%

--

Mar 11, 2025

Vestal Point Capital, LP

1.63M

3.54%

+1.23M

+307.50%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

2.19M

4.76%

-23.39K

-1.06%

Dec 31, 2024

TD Securities, Inc.

1.75M

3.79%

+1.75M

--

Dec 31, 2024

Acorn Capital Advisors, LLC

1.52M

3.29%

+1.52M

--

Dec 31, 2024

Pontifax Venture Capital

1.49M

3.22%

-1.00

-0.00%

Mar 14, 2024

3.990USD